Sankyo Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (1899)
Status: Acquired by Daiichi Sankyo (2005)

Organization Overview

First Clinical Trial
2001
NCT00185185
First Marketed Drug
1972
cyanocobalamin (berocca)
First NDA Approval
1997
troglitazone (prelay)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AM REGENT | SANKYO | Sankyo Shanghai Pharmaceuticals | Shanghai Sankyo Pharmaceuticals Co., Ltd.